Hematological Malignancies Conference 2019

Designed for hematologists, oncologists, pathologists, radiation oncologists and other health care providers who care for patients with hematologic malignancies, this program will focus on the most clinically-relevant research findings presented at recent national events, and how to apply this information in specific patient cases. 

Educational Objectives:

Following this program, participants should be able to:

  • Describe how to tailor the management of diffuse large B-cell lymphoma (DLBCL), including the possible use of novel therapeutic agents developed for the management of aggressive lymphoma.
  • Evaluate therapeutic approaches for CLL patients in the era of novel targeted agents.
  • Discuss the evolving changes in the management of Hodgkin’s lymphoma.
  • Examine different therapeutic approaches for relapsed/refractory MM, including identifying the role of maintenance therapy in relapsed/refractory MM.
  • Incorporate novel monoclonal antibodies in the management of relapsed/refractory MM.
  • Know the underlying pathogenesis of MDS, and describe how personalized medicine is changing treatment approaches in patients with MDS.
  • Know how risk adaptive stratification tools are being used to select treatments for young and elderly patients with AML.
  • Integrate gene sequencing information into the management of relapsed/refractory AML.
  • Identify biomarkers that can predict the clinical course of patients with different subtypes of MPD.
  • Explain how to integrate novel agents in the management of MPD patients. 
  • Identify who is the ideal patient for CART19 therapy in B-cell lymphoma, and learn the effectiveness of the therapy. 
  • Identify who is the ideal patient for CART therapy in MM, and learn the effectiveness of the therapy.   
  • Discuss the ABCs of recognizing and managing CRS and neurotoxicity in CART therapy patients.


Date: Saturday, May 18, 2019

Time: 7:30 a.m. - 3:45 p.m.

Marriott Syracuse Downtown  
100 East Onondaga Street
Syracuse, NY, 13202

Register Today




Roswell Park Comprehensive Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

Roswell Park designates this live educational activity for a maximum of 7.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The University at Buffalo School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  “The Roswell Park Comprehensive Cancer Center Hematological Malignancies Conference 2019,” is a knowledge-based activity and will award up to 7 contact hours of continuing pharmacy education. Continuing education credit will be uploaded to the CPE Monitor based on the morning and afternoon sessions attended by the participant and completion of the CE Attendance Form.


Directions and Parking:

Standard event parking, not including valet or overnight parking, is paid for by Roswell Park and will be FREE for attendees.  Free event parking will be available in the Harrison Place Parking Garage located at 100 Harrison Place, Syracuse, NY 13202.  Parking passes will be provided at the registration table located on the ground floor of the hotel.


Contact Information:

If you have any questions, please contact Denise Hammell at (716) 845-5706 or denise.hammell@roswellpark.org